Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 29;14(1):89.
doi: 10.1186/s13023-019-1060-2.

Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers

Affiliations

Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers

Magdalena Harrington et al. Orphanet J Rare Dis. .

Abstract

Background and methods: Metachromatic leukodystrophy (MLD) is a rare, autosomal recessive lysosomal storage disease caused by deficient activity of arylsulfatase A. Neurological involvement results in severe disability and premature death, but understanding of the natural history of the disease remains limited. In this study, 32 caregivers of patients with MLD in the USA (16 with late-infantile MLD; 16 with juvenile MLD) were interviewed about their experiences of the disease. Qualitative analysis of the interview transcripts was performed to gain insights into symptom onset, the diagnostic process and disease progression, with a focus on the differences between late-infantile and juvenile MLD.

Results: The mean ages of patients at interview were 7.6 years and 20.7 years for individuals with late-infantile and juvenile MLD, respectively. Patients with late-infantile MLD had a mean age of 1.5 years at symptom onset and 2.6 years at diagnosis. The most common initial symptoms in this group related to problems with gross motor function (12/16 patients); 11 patients never learned to walk independently. For patients with juvenile MLD, the mean ages at symptom onset and diagnosis were 8.7 years and 11.6 years, respectively. Cognitive or social/behavioural problems were the most common first reported symptoms in this group (9/16 and 7/16 patients, respectively); these were generally followed by deterioration in motor function. The rate of functional decline was more rapid in patients with late-infantile MLD than those with juvenile MLD; the mean time from first symptom to first functional loss was 1 year versus 6.1 years, respectively. Nine patients with juvenile MLD and three with late-infantile MLD had undergone a haematopoietic stem cell transplant; outcomes following transplant were variable.

Conclusions: Our data highlight clear overall differences in symptom profiles and disease progression between late-infantile and juvenile MLD, but also indicate some degree of interindividual variability within each subtype. These findings are broadly consistent with previously published descriptions of MLD and enhance our knowledge of the natural history of the disease, which ultimately should help to improve patient care and aid assessments of the effectiveness of disease-related interventions in the future.

Keywords: Caregiver; Lysosomal storage disease; MLD; Metachromatic leukodystrophy; Natural history; Qualitative research.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study was approved by Ethical and Independent Review Services, and informed consent was obtained from all individual participants included in the study. All research performed was in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication

Written informed consent for publication of the study results was obtained from the parents of the patients. A copy of the consent form is available for review by the Editor of this journal.

Competing interests

Magdalena Harrington was an employee of Shire (a Takeda company) when this research was performed, and is now an employee of Pfizer.

Diane Whalley, James Twiss, Rebecca Rushton and Susan Martin are employees of RTI Health Solutions.

Lynn Huynh and Hongbo Yang are employees of Analysis Group, Inc.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Categories of first symptomsa reported in patients with late-infantile and juvenile MLD. aSymptoms reported by parents were assigned to the given categories during analysis (e.g. gripping, finger movements or swallowing were classified as fine motor functions; head control, sitting and standing/walking were classified as gross motor functions). MLD, metachromatic leukodystrophy
Fig. 2
Fig. 2
Approximate timelines of disease-related events in patients with MLD (a) Mean timing of events following symptom onset for patients with late-infantile MLD and juvenile MLD (b) Sample individual disease timeline for a patient with late-infantile MLD (c) Sample individual disease timeline for a patient with juvenile MLD. When parents reported an approximate timing within an acceptably short range (e.g. < 1 year), the midpoint was used. ‘n’ corresponds to the number of patients for whom information on the timing of the event was available. aWalking loss was defined as a complete loss of ability to walk either assisted or unassisted. For late-infantile MLD, 11 patients who never learned to walk were not included in walking loss estimates. bA functional loss was defined as a complete loss of a gross motor function, a fine motor or related function, or speech. G-tube, gastrostomy tube

References

    1. Gieselmann V. Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr. 2008;97:15–21. doi: 10.1111/j.1651-2227.2008.00648.x. - DOI - PubMed
    1. Gieselmann V, Krägeloh-Mann I, et al. Metachromatic Leukodystrophy. In: Valle D, et al., editors. Scriver's online metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2018.
    1. Kehrer C, Blumenstock G, Gieselmann V, Krageloh-Mann I, German L. The natural course of gross motor deterioration in metachromatic leukodystrophy. Dev Med Child Neurol. 2011;53:850–855. doi: 10.1111/j.1469-8749.2011.04028.x. - DOI - PubMed
    1. Kehrer C, Groeschel S, Kustermann-Kuhn B, Burger F, Kohler W, Kohlschutter A, et al. Language and cognition in children with metachromatic leukodystrophy: onset and natural course in a nationwide cohort. Orphanet J Rare Dis. 2014;9:18. doi: 10.1186/1750-1172-9-18. - DOI - PMC - PubMed
    1. van Rappard DF, Boelens JJ, Wolf NI. Metachromatic leukodystrophy: disease spectrum and approaches for treatment. Best Pract Res Clin Endocrinol Metab. 2015;29:261–273. doi: 10.1016/j.beem.2014.10.001. - DOI - PubMed

Publication types